TSPYL2 and lung adenocarcinoma: Of the 58 cases with tumor and non-tumor paired lung adenocarcinoma samples, TSPX was downregulated in 47 cases (81%) as compared to the adjacent non-tumor specimens (Figure 1A), indicating that TSPX was significantly downregulated in lung adenocarcinoma (Wilcoxon matched pair test p-value < 0.0001).